RS Constellation I
Launched 2021

Danger Bio (DB) is developing a portfolio of first-in-class therapeutics targeting the mission-critical cellular systems responsible for detection of deadly threats like infection and injury, and activating immune responses against them. Imbalances in this biology provide the “pilot light” in many autoimmune and inflammatory diseases, and can drive potent immunosuppression and immune exhaustion in cancer microenvironments.

Biology Focus

Danger Bio targets the root of all immunity. Danger biology comprises the systems in every cell designed to detect and respond to signs of danger such as infection, injury, or cellular malfunctions, as well as those designed to prevent molecules from self from triggering "false alarms". Specific focal points include:

  • Intracellular danger sensors and key transcription factors
  • Innate immune activation signaling cascades
  • Clearance and editing mechanisms that remove self-ligand

Evidence Base

Significant human genetics and clinical evidence demonstrates that imbalances in this essential biology can drive autoimmune & inflammatory diseases, or if underactive, enable the spread of cancers or infections

  • Top 1% of all RS human genetics evidence for links to immune-mediated diseases
  • 1,000s of convergent, corroborating datapoints across multiple lines of evidence

Portfolio Composition

  • Over 20 active preclinical drug programs with 8 lead programs
  • 6 biological sub-themes and R&D teams
  • Modality-agnostic portfolio including small molecules, mAbs, mRNA, antisense oligonucleotides, RNAi, among other approaches

Disease Applications

Autoimmune & Inflammatory Diseases

  • 20+ targeted indications including SLE, RA, psoriasis, scleroderma, and rare unmet need autoimmune disorders
  • General therapeutic strategies: inhibit excess danger sensing, autoantigen presence, and/or innate immune activation to disrupt autoimmunity cycles

Cancer Immunotherapy

  • Targeting multiple difficult cancer settings with poor historical responses to immunotherapy
  • General therapeutic strategy: “Reboot” suppressive tumor microenvironments to improve response rates and durability of efficacy from immunotherapies

Scientific Leadership

World leaders in the fields of danger sensing, immunology, and virology.

Enterprise Value Creation

  • Building field-leading knowledge of assay and drug discovery strategies for difficult targets
  • Portfolio scoped to complete 5-7 IND-enabled programs with best-in-class drug discovery packages and multiple clinical paths
  • Constellation Series B planned for Q2 2023